Multivariate Cox regression analyses showed that the HER2 and triple-negative subtypes were associated with an increased risk of overall mortality (hazard ratio (HR) = 1.47, 95% CI, 1.03 to 2.10; HR = 1.87, 95% CI, 1.31 to 2.66, respectively) and breast cancer recurrence/disease-related mortality (HR = 1.32, 95% CI, 0.95 to 1.83; HR = 1.52, 95% CI, 1.09 to 2.11, respectively) after adjustment for age, education, income, BMI, radiotherapy, chemotherapy, immunotherapy, tamoxifen use, TNM stage, histologic grade, and tumor size. Here, ERBB2 is linked to breast cancer.